<DOC>
	<DOC>NCT02278991</DOC>
	<brief_summary>Objective of this study is to evaluate the safety and efficacy of Lutonix 035 Drug Coated Dilatation PTA Catheter with Bard LifeStent Vascular Stent (hereinafter referred to as LifeStent) for treatment of long (10-24 cm) lesions in the SFA.</brief_summary>
	<brief_title>Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1. Age ≥18 years 2. The subject is legally competent and able to understand the information on the study, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the Informed Consent Form (ICF) 3. Rutherford Category 24 4. Target de novo lesion(s) or nonstented restenotic lesion(s) has angiographic evidence of ≥50% stenosis or occlusion (by visual estimate) and is amenable to treatment with LifeStent and Lutonix DCB 5. Patients must be able to be treated with Lutonix DCB and LifeStent 6. Total treated segment(s) of 1024 cm in length 7. Target vessel reference diameter is 4.07.0 mm (by visual estimate) and able to be treated with available device size matrix 8. At least one patent native outflow artery to the ankle free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of outflow disease is NOT permitted; treatment of inflow disease is permitted prior to treatment with LifeStent) 1. Life expectancy of &lt;1 year 2. Inability to take required antiplatelet/anticoagulant medications per the LifeStent and Lutonix DCB IFU, or known contraindication (including allergic reaction) or sensitivity to contrast media, nickel, titanium or tantalum that cannot be adequately managed with pre and postprocedure medication 3. Intended treatment of outflow disease during the index procedure 4. Intended use of laser, atherectomy or cryoplasty during index procedure 5. Sudden symptom onset, acute vessel occlusion, or acute or subacute thrombus in target vessel 6. History of stroke within 3 months 7. History of myocardial infarction, thrombolysis or angina within 2 weeks of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>